Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

08/14/2026, 10:30 AM • The Motley Fool

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly announced it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in Q1 2027. The drug demonstrated 28.3% average weight loss over 80 weeks in phase 3 trials, outperforming competitors like Novo Nordisk's Wegovy. With strong Q2 financial results (48% revenue growth) and potential applications beyond obesity, Eli Lilly is positioned to expand its market lead.

08/07/2026, 6:30 PM • The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

08/07/2026, 3:28 PM • The Motley Fool

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

08/06/2026, 10:21 AM • The Motley Fool

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk announced that board members and executives received 74 shares each on August 5, 2026, through the company's Restricted Shares programme for the 100th Anniversary. The company also won a Dutch court injunction protecting patients from unapproved compounded semaglutide nasal spray, reinforcing patient safety and intellectual property rights. Additionally, Novo Nordisk reported adjusted operating profit of DKK 33,389 million for Q2 2026 and raised its full-year outlook.

08/06/2026, 3:18 AM • GlobeNewswire

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

Novo Nordisk secured a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V. for infringing its supplementary protection certificate on semaglutide by producing an unapproved nasal spray formulation. The court ordered Ceban to cease sales, remove product listings, disclose supply chain information, and reimburse legal costs. No semaglutide nasal spray has been approved by any regulatory authority.

08/05/2026, 9:42 AM • GlobeNewswire

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Eli Lilly has significantly outperformed Novo Nordisk in the booming GLP-1 obesity drug market, with Lilly commanding 60% market share compared to Novo's smaller portion of the combined 87% duopoly. While the obesity drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030, Lilly's stock has surged 58% over 52 weeks, whereas Novo has plummeted 62% since July 2024. However, Novo's recent launch of a pill-form obesity drug could shift the competitive landscape.

07/31/2026, 1:30 PM • The Motley Fool

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk announced that ziltivekimab failed to meet its primary endpoint in the ZEUS phase 3 trial, showing no significant reduction in major adverse cardiovascular events (MACE) despite achieving the expected biological effect of IL-6 pathway inhibition. The drug demonstrated a hazard ratio of 0.99 versus placebo in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company will take a non-cash impairment charge in Q3 2026 but maintains its 2026 profit outlook and plans to continue two additional cardiovascular trials (HERMES and ARTEMIS) expected to report in H1 2027.

07/31/2026, 7:21 AM • GlobeNewswire

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen is developing MariTide, a monthly weight loss injection, to compete with Eli Lilly's and Novo Nordisk's weekly GLP-1 drugs. While the monthly dosing offers convenience, MariTide's phase 2 efficacy data don't suggest it will outperform competitors. Eli Lilly and Novo Nordisk are advancing newer therapies including oral and combination drugs, positioning them ahead of Amgen in the competitive weight loss market.

07/29/2026, 7:30 AM • The Motley Fool

Novo Nordisk A/S - share repurchase programme

Novo Nordisk continues its DKK 15 billion share repurchase programme, having repurchased 25.9 million B shares worth DKK 7.16 billion as of 24 July 2026. The company has also filed a false advertising lawsuit against Eli Lilly over misleading GLP-1 medicine advertising campaigns.

07/27/2026, 6:48 AM • GlobeNewswire

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

New study finds GLP-1 receptor agonists associated with lower risk of alcohol-related hospitalization among adults with alcohol use disorder

A multi-system study analyzing electronic health records from over 40,000 adults with alcohol use disorder found that GLP-1 receptor agonists (semaglutide and tirzepatide) were associated with 22-26% lower risk of alcohol-related hospitalization in patients with type 2 diabetes, and 32% lower risk in patients with obesity, compared to alternative treatments. Researchers emphasize the need for randomized clinical trials to establish causation.

07/21/2026, 6:45 PM • GlobeNewswire

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.

Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising in GLP-1 weight-loss drug marketing. Novo claims Lilly's ads unfairly compare outdated lower doses of Wegovy to higher doses of Zepbound, ignoring the FDA-approved 7.2 mg Wegovy dose (approved March 2025) which shows comparable weight loss results. Lilly maintains its ads are accurate based on the 2024 SURMOUNT-5 head-to-head trial. The lawsuit seeks an injunction, corrective advertising, and damages, though analysts believe the impact on both stocks is likely minimal.

07/21/2026, 5:34 PM • The Motley Fool